Chronic myelogenous leukemia: Biology and therapy

Annals of Internal Medicine

Volumn 131, Issue 3, 1999, Pages 207-219

  Faderl, Stefan ^a   Talpaz, Moshe ^a   Estrov, Zeev ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AG 1112; AG 568; ALPHA INTERFERON; ANTISENSE OLIGONUCLEOTIDE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; MACROGOL; METHOTREXATE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ALLOGRAFT; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHIMERA; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; ENZYME ACTIVITY; HUMAN; IMMUNOMODULATION; ONCOGENE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVIEW; SPLENECTOMY; STEM CELL TRANSPLANTATION; VACCINATION; WHOLE BODY RADIATION;

EID: 0033520092     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-131-3-199908030-00008     Document Type: Review

References (144)

1. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet, and monocyte/macrophage. Am J Med. 1977;63:125-30.
2. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960:132:1497.
3. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. Clinical investigation of human alpha Interferon in chronic myelogenous leukemia. Blood. 1987;69:1280-8.
4. Brincker H. Population-based age-and sex-specific incidence rates in the 4 main types of leukemia. Scand J Haematol. 1982;29:241-9.
5. Baranovsky A, Myers MH. Cancer incidence and survival in patients 65 years of age and older. CA Cancer J Clin. 1986;36:26-41.
6. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood. 1993;82:691-703.
7. Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukemia seen at a referral centre over a 16-year period. Br J Haematol. 1997;96:111-6.
8. Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441-6.
9. Savage DG, Szydlo RM, Chase A, Apperley JF, Goldman JM. Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse. Br J Haematol. 1997;99:30-5.
10. Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol. 1988;25:49-61.
11. Griffin JD, Todd RF 3d, Ritz J, Nadler LM, Canellos GP, Rosenthal D, et al. Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood. 1983;61:85-91.
12. Derderian PM, Kantarjian HM, Talpaz M, O'Brien S. Cork A, Estey E, et al. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment responses, and prognosis. Am J Med. 1993;94:69-74.
13. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1970;243:290-3.
14. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med. 1988;319:990-8.
15. Specchia G, Mininni D, Guerrasio A, Palumbo G, Pastore D, Liso V. Ph positive acute lymphoblastic leukemia in adults: molecular and clinical studies. Leuk Lymphoma. 1995;18 Suppl:37-42.
16. Kurzrock R, Shtalrid M, Romero P, Kloetzer WS, Talpas M, Trujillo JM, et al. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukemia. Nature. 1987;325:631-5.
17. Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood. 1996;88:2410-4.
18. BCR/ABL hybrid protein [Abstract]. Blood. 1998;92 S1:94a.
19. Melo JV, Myint H, Galton DA, Goldman JM. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia. 1994;8:208-11.
20. Melo J. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype [Editorial]. Blood. 1996;88:2375-84.
21. Mitelman F. The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma. 1993;11 Suppl 1:11-5.
22. Ishikura H, Yufu Y, Yamashita S, Abe Y, Okamura T, Motomura S, et al. Biphenotypic blast crisis of chronic myelogenous leukemia: abnormalities of p53 and retinoblastoma genes. Leuk Lymphoma. 1997;25:573-8.
23. Marasca R, Luppi M, Barozzi P, Ferrari MG, Morselli M, Torelli G. P53 gene mutations in chronic myelogenous leukemia medullary and extramedullary blast crisis. Leuk Lymphoma. 1996:175-82.
24. Ahuja H, Bar-Eli M, Advani SH, Benchimol S, Cline MJ. Alterations in the p53 gene and the donal evolution of the blast crisis of chronic myelocytic leukemia Proc Natl Acad Sci U S A. 1989;86:6783-7.
25. Stuppia L, Calabrese G, Peila R, Guanciali-Franchi P, Morizio E, Spadano A, et al. p53 loss and point mutations are associated with suppression of apoptosis and progression of CML into myeloid blast crisis. Cancer Genet Cytogenet. 1997;98:28-35.
26. Serra A, Guerrasio A, Gaidano G, Rosso C, Rege-Cambrin G, Petroni D, et al. Molecular defects associated with the acute phase CML. Leuk Lymphoma. 1993:11 Suppl 1:25-8.
27. Guo JQ, Wang JY, Arlinghaus RB. Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients. Cancer Res. 1991;51:3048-51.
28. Hochhaus A, Reiter A, Skladny H, Reichert A, Saussele S, Hehlmann R. Molecular monitoring of residual disease in chronic myelogenous leukemia patients after therapy. Recent Results Cancer Res. 1998;144:36-45.
29. Muhlmann J, Thaler J, Hilbe W, Bechter O, Erdel M, Utermann G, et al. Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment. Genes Chromosomes Cancer. 1998;21:90-100.
30. Seong D, Kantarjian H, Ro J, Talpaz M, Xu J, Robinson JR, et al. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood. 1995;86:2343-9
31. Dewald GW, Wyatt WA, Juneau AL, Carlson RO, Zinsmeister AR, Jalal SM, et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood. 1998;91:3357-65.
32. Grand FH, Chase A, Iqbal S, Nguyen DX, Lewis JL, Martey SB, et al. A two-color BCR-ABL probe that greatly reduces the false positive and false negative rates for fluorescence in situ hybridization in chronic myeloid leukemia. Genes Chromosomes Cancer. 1998;23:109-15.
33. Cuneo A, Bigoni R, Emmanuel B, Smit E, Rigolin GM, Roberti MG, et al. Fluorescence in situ hybridization for the detection and monitoring of the Ph-positive clone in chronic myelogenous leukemia: comparison with metaphase banding analysis. Leukemia. 1998;12:1718-23.
34. Lissauer H. Zwei Fälle von Leucaemie. Klin Wochenschr. 1865;2:403-5.
35. Kantarjian HM, Keating MJ, Smith TL, Talpaz M, McCredie KB, Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med. 1990;88:1-8.
36. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984;63:789-99.
37. Pusey W. Report of cases treated with roentgen rays. JAMA. 1902;38: 911-9.
38. Galton D. Myleran m chronic myeloid leukemia. Lancet. 1953;1:208-13.
39. Kantarjian HM, Giles FJ, O'Brien SM, Talpaz M. Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. Hematol Oncol Clin North Am. 1998;12:31-80.
40. Kennedy BJ. Hydroxyurea therapy in chronic myelogenous leukemia. Cancer. 1972;29:1052-6.
41. De Simone C, Guerriero C, Guidi B, Rotoli M, Venier A, Tartaglione R. Multiple squamous cell carcinomas of the skin during long-term treatment with hydroxyurea. Eur J Dermatol. 1998;8:114-5.
42. Daoud MS, Gibson LE, Pittelkow MR. Hydroxyurea dermopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea. J Am Acad Dermatol. 1997:36(2 Pt 1): 178-82.
43. Weinlich G, Schuler G, Greil R, Kofler H, Fritsch P. Leg ulcers associated with long-term hydroxyurea therapy. J Am Acad Dermatol. 1998:39(2 Pt 2):372-4.
44. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. Blood. 1993;82: 398-407.
45. Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood. 1993;82:2235-8.
46. Bolin RW, Robinson WA, Sutherland J, Hamman RF. Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia. Cancer. 1982;50:1683-6.
47. Results of a prospective randomized trial of early splenectomy in chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Cancer. 1984;54:333-8.
48. Bouvet M, Babiera GV, Termuhlen PM, Hester JP, Kantarjian HM, Pollock RE. Splenectomy in the accelerated or blastic phase of chronic myelogenous leukemia: a single-institution, 25-year experience. Surgery. 1997;122:20-5.
49. Kantarjian HM, Vellekoop L, McCredie KB, Keating MJ, Hester J, Smith T, et al. Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia. J Clin Oncol. 1985;3:192-200.
50. Horowltz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1996;17 Suppl 3:S5-6.
51. Gratwohl A, Hermans J, Nlederwieser D, Frassoni F, Arcese W, Gahrton G, et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant. 1993;12:509-16.
52. Clift RA, Storb R. Marrow transplantation for CML: trie Seattle experience. Bone Marrow Transplant. 1996;17 Suppl 3:S1-3.
53. van Rhee F, Szydlo RM, Hermans J, Devergie A, Frassoni F, Arcese W, et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1997;20:553-60.
54. Clift RA, Appelbaum FR, Thomas ED. Treatment of chronic myeloid leukemia by marrow transplantation [Editorial]. Blood. 1993;82:1954-6.
55. Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Bensinger WI, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med. 1986;104:155-63.
56. Shepherd P, Richards S, Allan N. Survival after allogeneic bone marrow transplantation (BMT) in patients randomised into a trial of IFN-α versus chemotherapy: no significant adverse effect of prolonged IFN-α administration [Abstract]. Blood. 1995;86:94a.
57. Clift RA, Anasetti C. Allografting for chronic myeloid leukemia. Bailleres Clin Haematol. 1997;10:319-36.
58. Horowitz MM, Giralt S, Szydlo R, Goldman J, Veum-Stone J. Effect of prior interferon therapy on outcome of HLA-identical sibling marrow transplants for chronic myelogenous leukemia (CML) in first chronic phase [Abstract], Blood. 1996;88:682a.
59. Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood. 1994;84:2036-43.
60. Goldman JM, Gale RP, Horowitz MM, Biggs JC Champlin RE, Gluckman E, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse with T-cell depletion. Ann Intern Med. 1988;108:806-14.
61. Arcese W, Goldman IM, D'Arcangelo E, Schattenberg A, Nardi A, Apperly JF, et al. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. Bone Marrow Transplantation Group. Blood. 1993;82:3211-9.
62. Mrsíc M, Horowltz MM, Atkinson K, Biggs JC, Champlin RE, Ehninger G, et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant. 1992;9:269-75.
63. Higano CS, Raskind WH, Singer JW. Use of alpha interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation. Blood. 1992;80:1437-42.
64. Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-44.
65. Kolb HJ, Schattenberg A, Goldman JM, Herternstein B, Jacobsen N, Arcese W, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party on Chronic Leukemia. Blood. 1995;86:2041-50.
66. Kolb HJ, Mittermüller J, Clemm C, Holler E, Ledderose G, Brehm G, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462-5.
67. Kantarjian HM, Smith TL, O'Brien SM, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. The Leukemia Service. Ann Intern Med 1995;122:254-61.
68. Kantarjian HM, O'Brien SM, Anderline P, Talpaz M. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood. 1996;87:3069-81.
69. Alimena G, Morra E, Lazzarino M, Liberati AM, Montefusco E, Inverardi D, et al. Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood. 1988;72:642-7.
70. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, et al. Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronicphase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood. 1993;82:2975-84.
71. Mahon FX, Faberes C, Pueyo S, Cony-Makhoul P, Salmi R, Boiron JM, et al. Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferonalpha. Blood. 1998;92:4059-65.
72. Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, et al. A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood. 1995;86: 906-16.
73. Allan NC Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-α n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet. 1995;345:1392-7.
74. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group On Chronic Myeloid Leukemia. N Engl J Med. 1994;330:820-5.
75. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al. Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994;84:4064-77.
76. Allan NC, Richards SM, Shepherd PC. Interferon-α therapy with busulfan or hydroxyurea compared with either BU or HU alone in treatment of chronic phase CML. Results form MRC CML III trial [Abstract], Int J Hematol. 1996; 64(Suppl 1):S68.
77. Long-term follow-up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Blood. 1998;92:1541-8.
78. Ansari H, Hasford J, Hehlmann R. Fallacies of the intention-to-treat analysis. The German CML Study Group [Abstract]. J Mol Med. 1997;75: B243.
79. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a metaanalysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst. 1997;89:1616-20.
80. Sacchi S, Kantarjian HM, O'Brien SM. Beran M, Koller C, Pierce S, et al. Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia. Leukemia. 1997;11:1610-6.
81. Sokal JE, Leong SS, Gomez GA. Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia. Cancer. 1987; 59:197-202.
82. Cannistra S, Tantravahi R, Robertson MJ, Griffin J, Canellos GP. Low-dose cytosine arabinoside induces cytogenetic remissions in patients with stable phase chronic myeloid leukemia [Abstract]. Blood. 1990;76(Suppl 1):259a.
83. Sokal J, Bigner SH. Low-dose cytosine arabinoside by subcutaneous infusion in early and advanced chronic granulocytic leukemia (Abstract). Blood. 1986;68:233a.
84. Kantarjian HM, Keating MJ, Estey EH, O'Brien S, Pierce S, Beran M, et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-a and low-dose cytarabine. J Clin Oncol. 1992;10:772-8.
85. Arthur CK, Ma DD. Combined interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia. Acta Haematol. 1993; 89(Suppl 1):15-21.
86. Kantarilan HM, O'Brien S, Smith TL, Rios MB, Cortes J, Beran M, et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low dose cytosine arabinoside. J Clin Oncol. 1998;17:284-96.
87. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997;337:223-9.
88. Tura S. Cytarabine increases karyotypic response in alpha-IFN treated chronic myeloid leukemia patients: results of a national prospective randomized trial. Italian Cooperative Study Group on CML (ICSG on CML) [Abstract]. Blood. 1998;92 Suppl 1:317a.
89. Thaler J, Hilbe W, Apfelbeck U, Linkesch W, Sill H, Seewann H, et al. Interferon-alpha-2c and LD ara-c for the treatment of patients with CML: results of the Austrian Multi-Center Phase II Study. Leuk Res. 1997;21:75-80.
90. Silver RT, Szatrowski TP, Peterson B, Powell B, Larson R, Stock W, et al. Combined α-interferon (rhlFNα-2B) and low dose cytosine arabinoside for PH+ chronic phase chronic myeloid leukemia (CML) [Abstract]. Blood. 1996;88 (Suppl 1):633a.
91. Kantarjian HM, Talpaz M, Keating MJ. Estey EH. O'Brien S, Beran M, et al. Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 1991;68:1201-7
92. Mahon FX, Montastruc M, Faberes C, Reiffers J. Predicting complete cytogenetic response in chronic myelogenous leukemia patients treated with recombinant interferon a [Letter], Blood. 1994;84:3592-4.
93. Hochaus A, Lin F, Retter A, Skladny H, van Rhee F, Shepherd PC et al. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-α. Br J Haematol, 1995;91:126-31.
94. Kurzrock R, Estrov Z, Kantarjlan H, Talpaz M. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol. 1998;16:1526-31.
95. Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest. 1994;94:1383-9.
96. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood. 1995;86:3118-22.
97. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood. 1998;92:3362-7.
98. Shepherd PC, Richards SM, Allan NC Progress with interferon in CML-results of the MRC UK CML III Study. Bone Marrow Transplant. 1996;17 Suppl 3:S15-8.
99. Kantarjian HM, Keating MJ, Talpaz M, Walters RS, Smith TL, Cork A, et al. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med. 1987;83:445-54.
100. Thomas D, Kantarjlan H, O'Brien S, Cortes J, Giles FJ, Faderl S, et al. "Sudden" blaslic phase (SBP) transformation in the first 2 years (YRS) of interferon-α (IFN) therapy (RX) for chronic phase (CP) chronic myelogenous leukemia (CML) [Abstract]. Blood. 1998;92(Suppl 1):251a.
101. Wilhelm M, Bueso-Ramos C, O'Brien S, Pierce S, Keating M, Talpaz M, et al. Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia. Leukemia. 1998;12:65-70.
102. Straetmans N, Ma DD, Nevell DF, Arthur C. Evolution of bone marrow fibrosis and stromal antigenic expression in chronic myeloid leukemia on alpha interferon and Ara-C therapy. Hematopathol Mol Hematol. 1996;10: 213-22.
103. Horowitz MM, Giralt S, Szydlo R, Goldman J, Veum-Stone J. Effects of prior interferon therapy on outcome of HLA-identical sibling bone marrow transplants for chronic myelogenous leukemia (CML) in first chronic phase. International Bone Marrow Transplant Registry (IBMTR) [Abstract]. Exp Hematol. 1996;24:649.
104. Zuffa E, Bandini G, Bonini A, Teston N, Cirio TM, Rizzi S, et al. Outcome of allogeneic transplant in CML patients previously treated with alpha-interferon. Analysis in a single institution [Abstract]. Bone Marrow Transplant. 1995;15:518.
105. Tomás JF, López-Loreno JL, Requena MJ, Aguilar R, Steegmann JL, Camera R, et al. Absence of influence of prior treatment with interferon on the outcome of allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant. 1998;22:47-51.
106. Zuffa E, Bandini G, Bonini A, Santucci MA, Martinelli G, Rosti G, et al. Prior treatment with α-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia. Haematologica. 1998;83:231-6.
107. Giralt SA, Kantarjlan HM, Talpaz M, Rios MB, Del Giglio A, Andersson BS, et al. Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol. 1993;11:1055-61.
108. Beelen DW, Graeven U, Elmaagacli AH, Niederle N, Kloke O, Opalka B, et al. Prolonged administration of interferon-a in patients with chronicphase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood. 1995;85:2981-90.
109. Beelen DW, Elmaagacli AH, Schaefer UW. The adverse influence of pretransplant interferon-α (IFN-α) on transplant outcome after marrow transplantation for chronic phase chronic myelogenous leukemia increases with the duration of IFN-α exposure [Letter]. Blood. 1999;93:1779-80.
110. Pigneux A, Tanguy ML, Michallet M, Jouet JP, Kuentz M, Vernant JP, et al. Prior treatment with alpha Interferon does not adversely affect the outcome of allogeneic transplantation for CML [Abstract]. Blood. 1998; 92(Suppl 1):495a.
111. Morton AJ, Gooley T, Hansen JA, Appelbaum FR, Bruemmer B, Bjerke JW, et al. Association between pretransplant interferon-α and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood. 1998;92:394-401.
112. Hochhaus A, Hehlmann R, Kolb HJ, Muth A, Pfirrmann M, Holler E, et al. The outcome of allogenous bone marrow transplantation is strongly influenced by early discontinuation of interferon-α pretreatment in patients with chronic myeloid leukemia (CML) [Abstract]. Blood. 1998;92(Suppl 1): 495a.
113. McGlave P, Bartsch G, Anasetti C, Ash R, Beatty P, Gajewski J, et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood. 1993;81:543-50.
114. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962-8.
115. Gamis AS, Haake R, McGlave P, Ramsay NK. Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children. J Clin Oncol. 1993;11:834-8.
116. Gajewskl J, Gjertson D, Cecka M, Tonai R, Przeplorka D, Hunt L, et al. The impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant. 1997;3:76-82.
117. Devergle A, Apperley JF, Labopin M, Madrigal A, Jacobsen N, Carreras E, et al. European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1997;20:11-9.
118. Reiffers J, Goldman J, Meloni G, Cahn JY, Gratwohl A. Autologous stem cell transplantation in chronic myelogenous leukemia: a retrospective analysis of the European Group for Bone Marrow Transplantation. Chronic Leukemia Working Party of the EBMT. Bone Marrow Transplant. 1994;14: 407-10.
119. + cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood. 1994;83:3068-76.
120. Carella AM, Frassoni F, Melo J, Sawyers C, Eaves C Eaves A, et al. New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica. 1997;82:478-95.
121. Carella AM, Pollicardo N, Pungolino E, Raffo MR, Podesta M, Ferrero R, et al. Mobilization of cytogenetically "normal" blood progenitor cells by intensive conventional chemotherapy for chronic myeloid and acute lymphoblastic leukemia. Leuk Lymphoma. 1993;9:477-83.
122. Kantarjian HM, Talpaz M, Hester J, Feldman E, Korbling M, Liang J, et al. Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy. J Clin Oncol. 1995;13:553-9.
123. Talpaz M, Kantarjian H, Liang J, Calvert L, Hamer J, Tibbits P, et al. Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells. Blood. 1995;85:3257-63.
124. Simonsson B, Oberg G, Bjoreman MC, Bjorkholm M, Carneskog J, Gahrton G, et al. Intensive treatment in order to minimize the Ph-positive clone in CML. Danish-Swedish CML Group. Bone Marrow Transplant. 1996; 17(Suppl 3):S63-4.
125. O'Brien SM, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood. 1995;86:3322-6.
126. O'Brien S, Kantarjian H, Koller C, Feldman E, Beran M, Andreef M, et al. Sequential homoharringtonine and interferon-α in the treatment of early chronic phase chronic myelogenous leukemia. Blood. 1999;93:4149-53.
127. O'Brien S, Kantarjian H, Cortes J, Giles FJ, Beran M, Rius MB, et al. Simultaneous homoharringtonine (HHT) and Interferon alpha (IFN-α) therapy is an effective regimen in Philadelphia chromosome (Prepositive chronic myelogenous leukemia (CML) (Abstract]. Blood. 1998;92(Suppl 1):251a.
128. Issa JP, Baylin SG, Herman JG. DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia. 1997;11 Suppl 1:57-11.
129. Kantarjian HM, O'Brien SM, Keating M, Beran M, Estey E, Giralt S, et al. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia. 1997;11:1617-20.
130. Kantarjian HM, O'Brien SM, Estey E, Giralt S, Beran M, Rios MB, et al. Decitabine studies in chronic and acute myelogenous leukemia. Leukemia. 1997:11 Suppl 1:S35-6.
131. Talpaz M, Cortes J, O'Brien S, Keating M, Giles F, Rose E, et al. Phase I study of polyethylene glycol (PEG) Interferon alpha-2b (intron-A) in CML patients (Abstract]. Blood. 1998:92 Suppl 1:251a.
132. Ratajczak MZ, Kant JA, Luger SM. Hijya N, Zhang J, Zon G, et al. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligonucleotides. Proc Natl Acad Sci U S A. 1992;89:11823-7.
133. De Fabritiis P, Petti MC, Montefusco E, De Propris MS, Sala R, Bellucci R, et al. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. Blood. 1998;91:3156-62.
134. Maran A, Waller CF, Paranjape JM, Li G, Xiao W, Zhang K, et al. 2',5'-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells. Blood. 1998; 92:4336-43.
135. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science. 1995;267:1782-8.
136. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-6.
137. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 1997;90:3691-8.
138. le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst. 1999;91:163-8
139. Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res. 1998;4:1661-72.
140. Druker BJ, Sawyers CL, Talpaz M, Resta D, Peng B, Ford J, et al. Phase I trial of a specific ABL tyrosine kinase inhibitor, CGP 57148, in Interferon refractory chronic myelogenous leukemia patients [Abstract]. Proceedings of the American Society of Clinical Oncology. 1999;18:72.
141. Lim SH, Coleman S. Chronic myeloid leukemia as an immunological target. Am J Hematol. 1997;54:61-7.
142. Molldrem JJ, Clave E, Jiang YZ, Mavroudis D, Raptis A, Mensel N, et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood. 1997;90:2529-34.
143. Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche KO, et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 1997;89:1133-42.
144. Smit WM, Rijnbeek M, van Bergen CA, de Paus RA, Vervenne HA, van de Keur M, et al. Generation of dendritic cells expressing bcr/abl from CD34-positive chronic myeloid leukemia precursor cells. Hum Immunol. 1997;53:216-23.